<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00676065</url>
  </required_header>
  <id_info>
    <org_study_id>ZEG2006_03</org_study_id>
    <nct_id>NCT00676065</nct_id>
  </id_info>
  <brief_title>Long-term Active Surveillance Study for Oral Contraceptives (LASS)</brief_title>
  <official_title>Long-term Active Surveillance Study for Oral Contraceptives (LASS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Center for Epidemiology and Health Research, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Center for Epidemiology and Health Research, Germany</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to characterize and compare the risks of long-term use of oral
      contraceptives containing drospirenone and of other established oral contraceptives.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The LASS Study is a large, multinational, prospective, controlled, non-interventional,
      long-term cohort study that follows a series of cohorts. The cohorts consist of new users
      (first-ever users, switchers and restarters) of three different groups of oral contraceptives
      (OCs): OCs containing drospirenone (DRSP), OCs containing levonorgestrel (LNG) and OCs
      containing other progestogens. A &quot;non-interference&quot; approach is used to provide standardized,
      comprehensive, reliable information on these groups of OCs under routine medical conditions.

      The main clinical outcomes of interest for the long-term follow-up are arterial and venous
      thromboembolism as well as breast cancer. Regular, active contacts with the cohort members
      (=active surveillance) provide all necessary information on health-related events or changes
      in health status.

      The study is based on the existing long-term EURAS cohorts who are still in follow-up. LASS
      succeeds EURAS and prolongs the follow-up period for another five years. Total follow-up time
      of members of the long-term cohorts will be between 6 and 10 years. By means of annual
      contacts almost all relevant clinical outcomes will be captured. This will be accomplished by
      contacting the relevant physicians and by reviewing relevant source documents in the case of
      relevant clinical outcomes.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2001</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Arterial Thromboembolism</measure>
    <time_frame>Within 10 years</time_frame>
    <description>Arterial thromboembolism associated with the use of oral contraceptives containing drospirenone or levonorgestrel or other progestogens.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Venous Thromboembolism</measure>
    <time_frame>Within 10 years</time_frame>
    <description>Venous thromboembolism associated with the use of oral contraceptives containing drospirenone or levonorgestrel or other progestogens.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Breast Cancer</measure>
    <time_frame>Within 10 years</time_frame>
    <description>Breast cancer associated with the use of hormonal contraceptives either containing both drospirenone (DRSP) and ethinylestradiol (EE), levonorgestrel (LNG) or any other hormonal contraceptive without DRSP.</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">58303</enrollment>
  <condition>Arterial Thromboembolism</condition>
  <condition>Venous Thromboembolism</condition>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>Women who take oral contraceptives containing drospirenone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>Women who take oral contraceptives containing levonorgestrel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <description>Women who take oral contraceptives containing other progestogens</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Women attending offices of oral contraceptives prescribing physicians
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women who are prescribed an oral contraceptive and who are new users (first-ever
             users, switchers or restarters) of the formulation

        Exclusion Criteria:

          -  Women who do not consent to participate in the study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juergen Dinger, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center for Epidemiology and Health Research Berlin, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center for Epidemiology and Health Research</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 8, 2008</study_first_submitted>
  <study_first_submitted_qc>May 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2008</study_first_posted>
  <results_first_submitted>November 13, 2014</results_first_submitted>
  <results_first_submitted_qc>November 13, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 19, 2014</results_first_posted>
  <last_update_submitted>November 13, 2014</last_update_submitted>
  <last_update_submitted_qc>November 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Center for Epidemiology and Health Research, Germany</investigator_affiliation>
    <investigator_full_name>Juergen Dinger, MD, PhD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Contraception</keyword>
  <keyword>Thromboembolism</keyword>
  <keyword>Breast Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Contraceptives, Oral</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>In the LASS study, 59,510 women were recruited overall. Of these, 836 participants were excluded due to protocol violation (e.g. patient did not start OC use). Furthermore, 371 patients started treatment with non-oral contraceptives. These patients were followed-up but were not part of the per protocol Population (58,303 patients).</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Yasmin</title>
          <description>Users of oral contraceptives containing 3 mg DRSP and 30 mcg ethinylestradiol</description>
        </group>
        <group group_id="P2">
          <title>OC-LNG</title>
          <description>Users of oral contraceptives containing levonorgestrel</description>
        </group>
        <group group_id="P3">
          <title>OC-other</title>
          <description>Users of oral contraceptives containing other progestogens</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16534"/>
                <participants group_id="P2" count="15428"/>
                <participants group_id="P3" count="26341"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16534"/>
                <participants group_id="P2" count="15428"/>
                <participants group_id="P3" count="26341"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>DRSP/EE</title>
          <description>Users of oral contraceptives containing 3 mg DRSP and 30 mcg ethinylestradiol</description>
        </group>
        <group group_id="B2">
          <title>OC-LNG</title>
          <description>Users of oral contraceptives containing levonorgestrel</description>
        </group>
        <group group_id="B3">
          <title>OC-other</title>
          <description>Users of oral contraceptives containing other progestogens</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16534"/>
            <count group_id="B2" value="15428"/>
            <count group_id="B3" value="26341"/>
            <count group_id="B4" value="58303"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.9" spread="8.1"/>
                    <measurement group_id="B2" value="25.1" spread="8.7"/>
                    <measurement group_id="B3" value="24.8" spread="7.8"/>
                    <measurement group_id="B4" value="25.2" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16534"/>
                    <measurement group_id="B2" value="15428"/>
                    <measurement group_id="B3" value="26341"/>
                    <measurement group_id="B4" value="58303"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>This study was conducted in seven European countries: Austria, Belgium, Denmark, France, Germany, the Netherlands, and UK.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Europe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16534"/>
                    <measurement group_id="B2" value="15428"/>
                    <measurement group_id="B3" value="26341"/>
                    <measurement group_id="B4" value="58303"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Arterial Thromboembolism</title>
        <description>Arterial thromboembolism associated with the use of oral contraceptives containing drospirenone or levonorgestrel or other progestogens.</description>
        <time_frame>Within 10 years</time_frame>
        <population>The number of participants refers to the ITT study population. During the course od the study, women could for example stop use of oral contraception at any point of time. Therefore, the woman-years of exposure for each group are provided in addition.</population>
        <group_list>
          <group group_id="O1">
            <title>DRSP/EE</title>
            <description>Users of oral contraceptives containing 3 mg DRSP and 30 mcg ethinylestradiol</description>
          </group>
          <group group_id="O2">
            <title>OC-LNG</title>
            <description>Users of oral contraceptives containing levonorgestrel</description>
          </group>
          <group group_id="O3">
            <title>OC-other</title>
            <description>Users of oral contraceptives containing other progestogens</description>
          </group>
        </group_list>
        <measure>
          <title>Arterial Thromboembolism</title>
          <description>Arterial thromboembolism associated with the use of oral contraceptives containing drospirenone or levonorgestrel or other progestogens.</description>
          <population>The number of participants refers to the ITT study population. During the course od the study, women could for example stop use of oral contraception at any point of time. Therefore, the woman-years of exposure for each group are provided in addition.</population>
          <units>participants</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16534"/>
                <count group_id="O2" value="15428"/>
                <count group_id="O3" value="26341"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Woman-years, AT-population</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52278"/>
                <count group_id="O2" value="57539"/>
                <count group_id="O3" value="106221"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Tested null hypotheses: the ATE hazard ratio for DRSP/E2 vs. OCs containing LNG is higher or equal to 2.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The LASS study was designed to analyse rare events (incidence rate &lt;1 per 1,000 woman-years and ≥ 1 per 10,000 WY). 300,000 WY of observation would be sufficient to exclude a two-fold risk of rare events in users of DRSP compared to other oral contraceptives with a power (1-β) of 0.80 and an one-sided α of 0.05.</non_inferiority_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.2</ci_lower_limit>
            <ci_upper_limit>0.9</ci_upper_limit>
            <estimate_desc>Hazard ratio was adjusted for age, BMI, smoking, hypertension and family history</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Tested null hypotheses: the ATE hazard ratio for DRSP/E2 vs. OCs containing other progestogens is higher or equal to 2.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The LASS study was designed to analyse rare events (incidence rate &lt;1 per 1,000 woman-years and ≥ 1 per 10,000 WY). 300,000 WY of observation would be sufficient to exclude a two-fold risk of rare events in users of DRSP compared to other oral contraceptives with a power (1-β) of 0.80 and an one-sided α of 0.05.</non_inferiority_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.2</ci_lower_limit>
            <ci_upper_limit>0.9</ci_upper_limit>
            <estimate_desc>Hazard ratio was adjusted for age, BMI, smoking, hypertension and family history</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Venous Thromboembolism</title>
        <description>Venous thromboembolism associated with the use of oral contraceptives containing drospirenone or levonorgestrel or other progestogens.</description>
        <time_frame>Within 10 years</time_frame>
        <population>The number of participants refers to the ITT study population. During the course od the study, women could for example stop use of oral contraception at any point of time. Therefore, the woman-years of exposure for each group are provided in addition.</population>
        <group_list>
          <group group_id="O1">
            <title>DRSP/EE</title>
            <description>Users of oral contraceptives containing 3 mg DRSP and 30 mcg ethinylestradiol</description>
          </group>
          <group group_id="O2">
            <title>OC-LNG</title>
            <description>Users of oral contraceptives containing levonorgestrel</description>
          </group>
          <group group_id="O3">
            <title>OC-other</title>
            <description>Users of oral contraceptives containing other progestogens</description>
          </group>
        </group_list>
        <measure>
          <title>Venous Thromboembolism</title>
          <description>Venous thromboembolism associated with the use of oral contraceptives containing drospirenone or levonorgestrel or other progestogens.</description>
          <population>The number of participants refers to the ITT study population. During the course od the study, women could for example stop use of oral contraception at any point of time. Therefore, the woman-years of exposure for each group are provided in addition.</population>
          <units>participants</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16534"/>
                <count group_id="O2" value="15428"/>
                <count group_id="O3" value="26341"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Woman-years, AT population</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52278"/>
                <count group_id="O2" value="57539"/>
                <count group_id="O3" value="106221"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="53"/>
                    <measurement group_id="O3" value="144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Tested null hypotheses: the VTE hazard ratio for DRSP/E2 vs. OCs containing LNG is higher or equal to 2.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The LASS study was designed to analyse rare events (incidence rate &lt;1 per 1,000 woman-years and ≥ 1 per 10,000 WY). 300,000 WY of observation would be sufficient to exclude a two-fold risk of rare events in users of DRSP compared to other oral contraceptives with a power (1-β) of 0.80 and an one-sided α of 0.05.</non_inferiority_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.8</ci_lower_limit>
            <ci_upper_limit>1.7</ci_upper_limit>
            <estimate_desc>Hazard ratio was adjusted for age, BMI, current duration of use, and family history of VTE.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Tested null hypotheses: the VTE hazard ratio for DRSP/E2 vs. OCs containing other progestogens is higher or equal to 2.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The LASS study was designed to analyse rare events (incidence rate &lt;1 per 1,000 woman-years and ≥ 1 per 10,000 WY). 300,000 WY of observation would be sufficient to exclude a two-fold risk of rare events in users of DRSP compared to other oral contraceptives with a power (1-β) of 0.80 and an one-sided α of 0.05.</non_inferiority_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.5</ci_lower_limit>
            <ci_upper_limit>1.0</ci_upper_limit>
            <estimate_desc>Hazard ratio was adjusted for age, BMI, current duration of use, and family history of VTE.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Breast Cancer</title>
        <description>Breast cancer associated with the use of hormonal contraceptives either containing both drospirenone (DRSP) and ethinylestradiol (EE), levonorgestrel (LNG) or any other hormonal contraceptive without DRSP.</description>
        <time_frame>Within 10 years</time_frame>
        <population>The number of participants refers to the ITT study population. During the course od the study, women could for example stop use of oral contraception at any point of time. Therefore, the woman-years of exposure for each group are provided in addition.</population>
        <group_list>
          <group group_id="O1">
            <title>DRSP/EE</title>
            <description>Users of oral contraceptives containing 3 mg DRSP and 30 mcg ethinylestradiol</description>
          </group>
          <group group_id="O2">
            <title>OC-LNG</title>
            <description>Users of oral contraceptives containing levonorgestrel</description>
          </group>
          <group group_id="O3">
            <title>OC-other</title>
            <description>Users of oral contraceptives containing other progestogens</description>
          </group>
        </group_list>
        <measure>
          <title>Breast Cancer</title>
          <description>Breast cancer associated with the use of hormonal contraceptives either containing both drospirenone (DRSP) and ethinylestradiol (EE), levonorgestrel (LNG) or any other hormonal contraceptive without DRSP.</description>
          <population>The number of participants refers to the ITT study population. During the course od the study, women could for example stop use of oral contraception at any point of time. Therefore, the woman-years of exposure for each group are provided in addition.</population>
          <units>participants</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16534"/>
                <count group_id="O2" value="15428"/>
                <count group_id="O3" value="26341"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Woman-years</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52278"/>
                <count group_id="O2" value="57539"/>
                <count group_id="O3" value="106221"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Tested null hypotheses: the breast cancer hazard ratio for DRSP/E2 vs. OCs containing LNG is higher or equal to 2.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The LASS study was designed to analyse rare events (incidence rate &lt;1 per 1,000 woman-years and ≥ 1 per 10,000 WY). 300,000 WY of observation would be sufficient to exclude a two-fold risk of rare events in users of DRSP compared to other oral contraceptives with a power (1-β) of 0.80 and an one-sided α of 0.05.</non_inferiority_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.5</ci_lower_limit>
            <ci_upper_limit>1.4</ci_upper_limit>
            <estimate_desc>Hazard ratio was adjusted for age, BMI, smoking, educational level and age at menarche.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Tested null hypotheses: the breast cancer hazard ratio for DRSP/E2 vs. OCs containing other progestogens is higher or equal to 2.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The LASS study was designed to analyse rare events (incidence rate &lt;1 per 1,000 woman-years and ≥ 1 per 10,000 WY). 300,000 WY of observation would be sufficient to exclude a two-fold risk of rare events in users of DRSP compared to other oral contraceptives with a power (1-β) of 0.80 and an one-sided α of 0.05.</non_inferiority_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.6</ci_lower_limit>
            <ci_upper_limit>1.5</ci_upper_limit>
            <estimate_desc>Hazard ratio was adjusted for age, BMI, smoking, educational level and age at menarche.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Information on adverse events was collected over a time period of 10 years.</time_frame>
      <desc>ITT population. All study participants were asked for adverse events at each follow-up.</desc>
      <group_list>
        <group group_id="E1">
          <title>DRSP/EE</title>
          <description>Users of oral contraceptives containing 3 mg DRSP and 30 mcg ethinylestradiol</description>
        </group>
        <group group_id="E2">
          <title>OC-LNG</title>
          <description>Users of oral contraceptives containing levonorgestrel</description>
        </group>
        <group group_id="E3">
          <title>OC-other</title>
          <description>Users of oral contraceptives containing other progestogens</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>ICD-10</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1912" subjects_at_risk="16534"/>
                <counts group_id="E2" subjects_affected="2121" subjects_at_risk="15428"/>
                <counts group_id="E3" subjects_affected="3936" subjects_at_risk="26341"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Diseases of the blood and the bloodforming organs</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="16534"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="15428"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="26341"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiovascular system</sub_title>
                <counts group_id="E1" subjects_affected="198" subjects_at_risk="16534"/>
                <counts group_id="E2" subjects_affected="226" subjects_at_risk="15428"/>
                <counts group_id="E3" subjects_affected="425" subjects_at_risk="26341"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="16534"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="15428"/>
                <counts group_id="E3" subjects_affected="53" subjects_at_risk="26341"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Endocrine diseases</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="16534"/>
                <counts group_id="E2" subjects_affected="74" subjects_at_risk="15428"/>
                <counts group_id="E3" subjects_affected="96" subjects_at_risk="26341"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="16534"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="15428"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="26341"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Digestive system</sub_title>
                <counts group_id="E1" subjects_affected="248" subjects_at_risk="16534"/>
                <counts group_id="E2" subjects_affected="265" subjects_at_risk="15428"/>
                <counts group_id="E3" subjects_affected="503" subjects_at_risk="26341"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infectious diseases</sub_title>
                <counts group_id="E1" subjects_affected="86" subjects_at_risk="16534"/>
                <counts group_id="E2" subjects_affected="86" subjects_at_risk="15428"/>
                <counts group_id="E3" subjects_affected="171" subjects_at_risk="26341"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury, poisoning, accidents, etc.</sub_title>
                <counts group_id="E1" subjects_affected="337" subjects_at_risk="16534"/>
                <counts group_id="E2" subjects_affected="358" subjects_at_risk="15428"/>
                <counts group_id="E3" subjects_affected="651" subjects_at_risk="26341"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscoskeletal system &amp; connective tissue</sub_title>
                <counts group_id="E1" subjects_affected="206" subjects_at_risk="16534"/>
                <counts group_id="E2" subjects_affected="233" subjects_at_risk="15428"/>
                <counts group_id="E3" subjects_affected="403" subjects_at_risk="26341"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasms, malignant</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="16534"/>
                <counts group_id="E2" subjects_affected="72" subjects_at_risk="15428"/>
                <counts group_id="E3" subjects_affected="124" subjects_at_risk="26341"/>
              </event>
              <event>
                <sub_title>Neoplasms, benign</sub_title>
                <counts group_id="E1" subjects_affected="96" subjects_at_risk="16534"/>
                <counts group_id="E2" subjects_affected="97" subjects_at_risk="15428"/>
                <counts group_id="E3" subjects_affected="179" subjects_at_risk="26341"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Pregnancy, delivery &amp; puerperium</sub_title>
                <description>SAEs that occurred within 3 months after stop of OC use, were attributed to the last hormonal contraceptive used by the women. Therefore, pregnancy related SAEs on OC cohorts do not necessarily reflect unwanted pregnancies during HC use</description>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="16534"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="15428"/>
                <counts group_id="E3" subjects_affected="99" subjects_at_risk="26341"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychiatric &amp; neurological disorders</sub_title>
                <counts group_id="E1" subjects_affected="114" subjects_at_risk="16534"/>
                <counts group_id="E2" subjects_affected="136" subjects_at_risk="15428"/>
                <counts group_id="E3" subjects_affected="274" subjects_at_risk="26341"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Genitourinary system</sub_title>
                <counts group_id="E1" subjects_affected="279" subjects_at_risk="16534"/>
                <counts group_id="E2" subjects_affected="290" subjects_at_risk="15428"/>
                <counts group_id="E3" subjects_affected="572" subjects_at_risk="26341"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory system</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="16534"/>
                <counts group_id="E2" subjects_affected="64" subjects_at_risk="15428"/>
                <counts group_id="E3" subjects_affected="128" subjects_at_risk="26341"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin</sub_title>
                <counts group_id="E1" subjects_affected="82" subjects_at_risk="16534"/>
                <counts group_id="E2" subjects_affected="97" subjects_at_risk="15428"/>
                <counts group_id="E3" subjects_affected="200" subjects_at_risk="26341"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16534"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15428"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26341"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>In non-experimental studies the possibility of bias and residual confounding can never be entirely eliminated. The findings may exclude large, but not small relative risks.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Juergen Dinger, MD, PhD</name_or_title>
      <organization>Center for Epidemiology and Health Research Germany</organization>
      <phone>+49 30 945 101 20</phone>
      <email>dinger@zeg-berlin.de</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

